The polymerase chain reaction (PCR) was used to detect hepatitis C (HCV) viral sequences (HCV-RNA) in clotting factor concentrates that had been stored at 4 degrees C for 1 to 16 years. A total of 43 concentrates were tested, comprising 31 batches of factor VIII, 6 of factor IX, 2 of antithrombin III, 3 of FEIBA, and 1 of factor VII. HCV-RNA was detected in 13 of the 43 batches (30.2%). Concent...

Coagulation factor VII (FVII) is a vitamin K dependent glycoprotein of the extrinsic pathway and initiates coagulation by binding to tissue factor. Activated prothrombin-complex concentrate ([APCC] FEIBA), an activated prothrombin complex concentrate that is plasma-derived, has also been demonstrated to bypass the need for FVIII or factor IX, resulting in hemostasis. Both APCC and recombinant f...

Introduction Haemophilia A is a congenital bleeding disorder due to the lack of coagulation factor VIII (FVIII). The standard treatment is based on administration of plasma-derived or recombinant FVIII concentrates. The natural history of the disease includes recurrent bleeding into joints and the major long-term disability in affected patients is chronic arthropathy. The life expectancy of pat...

Marcus Stockschläder1; Leilani Ruf2; Anne Linderer3; Thomas Schroeder2; Wolfram T. Knoefel3; Rainer Haas2; Günther Giers1; Andrea Gerhardt1; Christoph Sucker1; Rainer B. Zotz1; Rüdiger E. Scharf1 1Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany; 2Department of Haematology, Oncology, and Clinical Immunology, Heinrich Heine Univers...

OBJECTIVE To compare the cost-effectiveness of three treatment regimens using recombinant activated Factor VII (rFVIIa), NovoSeven, and activated prothrombin-complex concentrate (APCC), FEIBA VH, for home treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. METHODS A literature-based, decision-analytic model was developed to compare three treatment regimens. The regim...

Thromb Haemost 2008; 100: 179–180 Protamine sulphate neutralizes the anticoagulant effect of unfractionated heparin (UFH), and this effect can easily be demonstrated by a variety of assay systems, including the traditional activated partial thromboplastin time (aPTT), as well as anti-factor Xa assays, or thrombin generation tests such as the Calibrated Automated Thrombogram (CAT) (1). Protamine...